SophIA Award for the start-up NeuroPin

Published on November 25, 2022 Updated on December 14, 2022

NeuroPin (Inria Start-up Studio & 3IA Start-it-up) received a SophIA Award at the SophIA Summit 2022.

NeuroPin received a SophIA Award at the SophIA Summit closing ceremony on November 25, 2022. It is a start-up company at the Inria Start-up Studio at Sophia-Antipolis. The NeuroPin start-up project benefits from the 3IA Côte d'Azur's Start-it-up program, of which it was the laureate in November 2022.

Antonia Machlouzarides-Shalit (PhD) is the founder and CEO of NeuroPin. She is a neuroscientist with biomedical and computational expertise, with the objective of advancing the detection and diagnoses of neuropathologies with neuroimaging. Her PhD involved using neuroanatomy to develop novel methods for brain mapping, and has additional expertise in MRI, DTI, EEG, tractography and neurodevelopmental disorders.

We asked Antonia to present her start-up. Read on to learn more!

"NeuroPin is developing AI-based medical software to optimize neuroradiology diagnostics. It assists radiologists by automatically localizing and robustly measuring, in 2D and 3D, brain regions and any anomalous findings, for single or multiple time-points. It enables faster, more accurate reporting and communicating of results, to more effectively guide diagnosis and treatment.

Variations in brain area measurements may have substantial medical significance in patients’ health. Many current practices to track changes are time-consuming, highly subjective, and adversely affected by technical factors such as inter-scanner variabilities. NeuroPin uses federated learning to compensate for human and technical variabilities in medical imaging diagnostics, and provides robust and reproducible measurements  – saving diagnostic time.
 


  segmentation and volumetry of 62 brain regions on an MRI image


NeuroPin will improve the radiology workflow in three main ways: 

  1. It faster localizes and identifies brain regions, normal or abnormal, for multiple scans; 

  2. It provides more quantitative and objective measurements of relevant findings, and comparison of these results to available previous scans, at greatly enhanced speed; 

  3. It enables population-level analysis of biomarker trends or response to treatment, thus enabling the establishment of safer prediction parameters.

Medical facilities and patients will benefit in multiple ways from the improved use of radiologists’ time and expertise; personalized quantifiable benchmarks will be established, for multiple time-point radiological analyses; and quantifiable, accurate brain charts for population-level comparisons will be compiled. These objectives are particularly pertinent for neurodevelopmental disorders, which will constitute our initial focus for application."

3IA Côte d'Azur is happy to see promising start-up projects succeed. Congratulations to the NeuroPin team!